

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Lunger John</u> (Last) (First) (Middle) <u>C/O ADAPTIMMUNE THERAPEUTICS PLC,</u> <u>60 JUBILEE AVENUE, MILTON PARK</u> (Street) <u>ABINGDON X0 OX14 4RX</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Adaptimmune Therapeutics PLC [ADAP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) Chief Patient Supply Officer
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/17/2023</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Option to purchase Ordinary Shares	\$0.31 ⁽¹⁾	01/17/2023		A		1,407,072		(2)	01/17/2033	Ordinary Shares	1,407,072	\$0	1,407,072	D	
Option to purchase Ordinary Shares	\$0.0012 ⁽³⁾	01/17/2023		A		314,256		(4)	(5)	Ordinary Shares	314,256	\$0	314,256	D	
Option to purchase Ordinary Shares	\$0.0012 ⁽⁶⁾	01/17/2023		A		190,920			01/17/2024 03/15/2025	Ordinary Shares	190,920	\$0	190,920	D	

Explanation of Responses:

- The exercise price was converted from GBP0.26 based on an exchange rate of U.S.\$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.
- The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.\$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.
- The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
- The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.\$ 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

/s/ John Lunger 01/17/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.